DALLAS, MARCH 21, 2026 —
What You Need To Know
- A new once-daily pill called enlicitide cut LDL — “bad” cholesterol — by 60% in a landmark Phase 3 clinical trial published in the New England Journal of Medicine
- The drug matches the effectiveness of injectable cholesterol medications that most doctors almost never prescribe — because patients refuse the needle
- The FDA has granted enlicitide a National Priority Voucher to fast-track approval — meaning millions of Americans could have access to it within the next 12 to 18 months
For decades, the most effective cholesterol medications in the world have sat largely unused in doctors’ prescription pads — because the best ones required an injection. Patients refused. Doctors stopped offering them. And tens of millions of Americans with dangerously high cholesterol continued having heart attacks and strokes that a medication could have prevented.
A pill just changed that equation.
What Enlicitide Does — And Why It Is Different
Enlicitide is a new type of cholesterol drug developed by Merck that works by targeting a protein in the bloodstream called PCSK9 — the same protein targeted by the injectable medications that have been available since 2015 but rarely used. PCSK9 reduces the number of LDL receptors on liver cells, effectively slowing the liver’s ability to clear bad cholesterol from the bloodstream. Block PCSK9, and those receptors multiply — pulling dramatically more LDL out of the blood.
The injectable PCSK9 inhibitors already on the market — evolocumab and alirocumab — reduce LDL cholesterol by roughly 60% and are extraordinarily effective. The problem is that the vast majority of primary care physicians almost never prescribe them, and a substantial minority of cardiologists don’t either. The reason, cardiologist and lead trial researcher Dr. Ann Marie Navar of UT Southwestern Medical Center explained, is likely simple: they are only available as injections. Patients who might benefit refuse. Doctors stop offering.
Enlicitide is taken once a day as a pill. That one change is what makes this discovery significant.
What the Trial Found
The Phase 3 CORALreef Lipids trial enrolled 2,909 patients across 168 sites in 14 countries — one of the largest cholesterol drug trials in years. Participants had either established heart disease or were at significant risk for it, and all were already taking statins at moderate or high doses. Their cholesterol levels were still dangerously high despite that medication.
| Outcome | Enlicitide Group | Placebo Group |
|---|---|---|
| LDL reduction at 24 weeks | -57.1% | +3.0% |
| LDL reduction at 52 weeks | -47.6% | Rising |
| Non-HDL cholesterol reduction | -53.4% | Minimal |
| Apolipoprotein B reduction | -50.3% | Minimal |
| Safety difference vs placebo | None apparent | — |
The results held steady across a full year of follow-up. There were no apparent differences in adverse events between the enlicitide and placebo groups — meaning the drug appears as safe as it is effective at this stage of testing.
“These reductions in LDL cholesterol are the most we have ever achieved with an oral drug by far since the development of statins,” Dr. Navar said. A separate clinical trial is already underway to determine whether those LDL reductions translate into actual reductions in heart attacks and strokes — the ultimate proof of concept that would complete enlicitide’s case for widespread use.
Why 86 Million Americans Should Pay Attention
High LDL cholesterol — the kind that builds up in artery walls and causes heart attacks and strokes — affects approximately 86 million adults in the United States. It is the single most treatable risk factor for cardiovascular disease, which remains the leading cause of death in America. Fewer than half of patients with established heart disease currently reach the LDL targets their doctors recommend, even with statins.
The gap between what is medically possible and what patients actually achieve comes down to adherence — taking medication consistently enough and at high enough doses to matter. Research by Dr. Navar’s own group has shown that patients who take pills are roughly 20% more adherent to their treatment regimens than patients who must inject. That gap — 20% better adherence applied across tens of millions of patients — translates into a meaningful reduction in preventable heart attacks and strokes at the population level.
Common Misconceptions
Misconception 1: “My statin is already controlling my cholesterol so I don’t need anything stronger.” In the trial, all 2,909 participants were already on statins — and their cholesterol was still dangerously high. Statins lower LDL by 30-50% for most patients. Some patients need more. PCSK9 inhibitors like enlicitide can provide it.
Misconception 2: “If this drug were really effective the FDA would have approved it already.” The FDA granted enlicitide a National Priority Voucher — a designation used to accelerate review of drugs addressing significant unmet medical needs. The approval timeline is 12-18 months, not years.
Misconception 3: “New drugs are always too expensive.” Enlicitide’s pricing has not been announced — but the competitive pressure of entering a market where injectable alternatives exist will be a significant pricing constraint. Merck has a commercial incentive to price the oral version accessibly enough to displace the injectable competitors.
What Patients Should Know
Enlicitide is not yet approved. It cannot be prescribed today. But if you have high LDL cholesterol that is not adequately controlled by your current statin — or if you have been told you need a PCSK9 inhibitor but have declined the injection — this drug is worth asking your doctor about now.
The clinical trial data is published. The FDA review is underway. And the cardiologists who have spent years watching patients refuse injectable cholesterol medications see in enlicitide something genuinely rare: a drug that is as good as the best option available — and that patients might actually take.
Heart disease kills more Americans than any other condition. Cholesterol is its most controllable risk factor. A daily pill that cuts bad cholesterol by 60% — with no injection required — is not a minor development. It is the kind of advance that, if it clears FDA approval as expected, could prevent hundreds of thousands of heart attacks and strokes every year.
The needle has always been the problem. The pill might finally be the answer.
